

National Institute for Health and Clinical Excellence

Review of CG 57: Atopic eczema in children: Management of atopic eczema in children from birth up to 12 years

Guideline Review Consultation Comments Table:

Please enter the name of your registered stakeholder organisation below.	
NICE is unable to accept comments from non-registered organisation or individuals. If you wish your comments to be considered please register via the NICE website or contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.	
Stakeholder Organisation:	British Association of Dermatologists
Name of commentator:	Michael J. Tidman, Chair of Therapy & Guidelines Subcommittee

Stakeholder	Agree Disagree with proposal to not update?	Comments Please insert each new comment in a new row.	Comments on areas excluded from original scope	Comments on equality issues
B.A.D	Agree	In due course, the role of topical tacrolimus as a maintenance therapy should be included.	The value of probiotics has not been established. Mention of this is made in the SIGN guideline on atopic eczema.	None

Please add extra rows as needed

Please email this form to: eczemachildren@nice.org.uk

Closing date: 9am on 3rd June 2011

PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.